Glucocorticoid Effects in the Human Placenta: Evidence That Dexamethasone-Mediated Inhibition of Fibronectin Expression in Cytotrophoblasts Involves a Protein Intermediate1
Diana Y. Yoon,
Yuehong Ma,
Graciela Krikun,
Charles J. Lockwood,
Linda LaChapelle and
Seth Guller
Departments of Obstetrics and Gynecology (Y.M., G.K., C.J.L., L.L.,
S.G.) and Biochemistry (S.G.), New York University Medical Center, New
York, New York 10016
Address all correspondence and requests for reprints to: Dr. Seth Guller, Department of Obstetrics and Gynecology, New York University Medical Center, Tisch Hospital Room 531, 550 First Avenue, New York, New York 10016.
Oncofetal fibronectin is an extracellular matrix protein thatis
suggested to play an important role in regulating adherenceat
uterine-placental interfaces. The purpose of the presentstudy was to
elucidate a mechanism through which glucocorticoids(GCs) inhibit the
synthesis of FN in human placenta as partof their matrix-suppressive
action near parturition. We observedthat treatment of cytotrophoblasts
isolated from human termplacentas for 48 h with 10-7
mol/L dexamethasone (DEX) down-regulatedlevels of FN expression to
1319% of control levels inimmunoprecipitation, Northern blotting,
and enzyme-linked immunosorbentassay experiments. Conversely, GC
treatment increased FN expressionin placental fibroblasts to
164310% of control levelsin Northern blotting and enzyme-linked
immunosorbent assay procedures,suggesting that GC-mediated suppression
of FN expression isspecific to cytotrophoblasts. Results indicated
that the DEX-mediatedsuppression of FN expression in cytotrophoblasts
was not mediatedthrough changes in the stability of FN messenger
ribonucleicacid (mRNA). Run-on transcription assays using isolated
nucleisuggested that GC treatment did not markedly affect
transcriptionof the FN gene in cytotrophoblasts. To test whether the
GC-mediatedsuppression of FN expression was mediated through a protein
intermediate,levels of FN mRNA were examined by Northern blotting in
cellstreated for 48 h with and without 10-7 mol/L
DEX and cycloheximide(CHX; 125 ng/mL). We observed that CHX treatment
increased FNexpression in DEX-treated cells to 91% of control values.
Wenoted that whereas the presence of 100300 ng/mL CHX reversedthe
DEX-mediated inhibition of FN mRNA expression in cytotrophoblasts,it
did not alter the overall rates of protein synthesis in DEX-treatedand
control cells. These data suggest that suppression of FNmRNA
expression by GC in cytotrophoblasts requires de novo
proteinsynthesis and is mediated through a short lived intermediate,
thesynthesis of which is inhibited at low concentrations of CHX.Thus,
GC-induced protein intermediates may influence uterine-placental
adherenceby modulating levels of oncofetal FN at sites of
uterine-placentalcontact.
This article has been cited by other articles:
J. P. van Beek, H. Guan, L. Julan, and K. Yang Glucocorticoids Stimulate the Expression of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 in Cultured Human Placental Trophoblast Cells
J. Clin. Endocrinol. Metab.,
November 1, 2004;
89(11):
5614 - 5621.
[Abstract][Full Text][PDF]
M.-J. Lee, Y. Ma, L. LaChapelle, S. S. Kadner, and S. Guller Glucocorticoid Enhances Transforming Growth Factor-{beta} Effects on Extracellular Matrix Protein Expression in Human Placental Mesenchymal Cells
Biol Reprod,
May 1, 2004;
70(5):
1246 - 1252.
[Abstract][Full Text][PDF]
Y. Ma, C. J. Lockwood, A. L. Bunim, D. A. Giussani, P. W. Nathanielsz, and S. Guller Cell Type-Specific Regulation of Fetal Fibronectin Expression in Amnion: Conservation of Glucocorticoid Responsiveness in Human and Nonhuman Primates
Biol Reprod,
June 1, 2000;
62(6):
1812 - 1817.
[Abstract][Full Text]
J. S. Ryu, R. J. Majeska, Y. Ma, L. LaChapelle, and S. Guller Steroid Regulation of Human Placental Integrins: Suppression of {alpha}2 Integrin Expression in Cytotrophoblasts by Glucocorticoids
Endocrinology,
September 1, 1999;
140(9):
3904 - 3908.
[Abstract][Full Text]
L. I. McKay and J. A. Cidlowski Molecular Control of Immune/Inflammatory Responses: Interactions Between Nuclear Factor-{kappa}B and Steroid Receptor-Signaling Pathways
Endocr. Rev.,
August 1, 1999;
20(4):
435 - 459.
[Abstract][Full Text][PDF]